Research programme: dermatological disorder therapeutics - Ferndale Therapeutics/Crescita TherapeuticsAlternative Names: CTX 103; Mical (2); Mical 2
Latest Information Update: 13 Sep 2016
At a glance
- Originator Nuvo Research
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Skin disorders
Most Recent Events
- 31 Dec 2014 Preclinical trials in Skin disorders in Canada (Topical)
- 23 Apr 2014 Early research in Skin disorders in Canada (Topical)